Skip to main content
$66.94 $3.31 (5.2%)

04:00 PM EDT on 09/28/22

CRISPR Therapeutics (NASDAQ:CRSP)

CAPS Rating: 5 out of 5

Current Price $66.94 Mkt Cap $5.0B
Open $64.16 P/E Ratio 16.43
Prev. Close $66.94 Div. (Yield) $0.00 (0.0%)
Daily Range $63.72 - $67.43 Volume 1,271,237
52-Wk Range $42.51 - $114.23 Avg. Daily Vol. 1,165,089

Caps

How do you think NASDAQ:CRSP will perform against the market?

Add Stock to CAPS Watchlist

All Players

440 Outperform
5 Underperform
 

All-Star Players

43 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CRSP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFAdriaCimino (< 20)
Submitted January 14, 2022

A lot depends on Crispr's candidate for blood disorders. Crispr and partner Vertex aim to file for regulatory approval in late 2022. If this treatment gets the nod, I expect big gains for Crispr. That said, the stock is risky and if the treatment… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:CRSP Summary

Fools bullish on NASDAQ:CRSP are also bullish on:

Fools bearish on NASDAQ:CRSP are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CRSP.

Recs

0
Member Avatar lemiwinx (45.10) Submitted: 7/18/2022 11:56:27 AM : Outperform Start Price: $79.20 NASDAQ:CRSP Score: -12.68

CRISPR gene editing is super exciting technology. Massive potential for the technology. Not much going on in the SR, waiting for the pipelines to mature.

Recs

0
Member Avatar emtking (45.62) Submitted: 6/11/2022 11:44:05 AM : Outperform Start Price: $59.26 NASDAQ:CRSP Score: +15.42

Short term pain for longer term gain. Great technology, but competition now in the space.

Recs

1
Member Avatar TMFAdriaCimino (< 20) Submitted: 1/14/2022 5:08:29 PM : Outperform Start Price: $66.51 NASDAQ:CRSP Score: +20.06

A lot depends on Crispr's candidate for blood disorders. Crispr and partner Vertex aim to file for regulatory approval in late 2022. If this treatment gets the nod, I expect big gains for Crispr. That said, the stock is risky and if the treatment doesn't get approval, Crispr shares likely will suffer. So far, I'm optimistic considering clinical trial data.

Leaderboard

Find the members with the highest scoring picks in CRSP.

Score Leader

CMFMLove

CMFMLove (42.58) Score: +322.89

I'm generally bad at CAPS but I may have gotten this pick right. There's a long way to go, however, until we see commercial results from this technology.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
CMFMLove 42.58 6/13/2017 6/23/2022 Outperform NS $14.10 +374.75% +51.86% +322.89 1 Comment
Momentum21 80.79 10/24/2016 Outperform 5Y $14.05 +376.44% +72.51% +303.93 0 Comment
Playa14 < 20 6/9/2017 5/18/2022 Outperform 5Y $15.13 +342.43% +51.79% +290.64 0 Comment
prankjt17530 35.99 2/13/2017 Outperform 5Y $15.21 +340.11% +59.65% +280.46 0 Comment
SHOPNVDA < 20 6/26/2017 Outperform 5Y $16.84 +297.51% +51.91% +245.60 0 Comment
Capitalism 69.54 5/15/2017 Outperform 5Y $17.05 +292.61% +54.30% +238.31 1 Comment
TMFFishBiz < 20 11/13/2017 Outperform 5Y $17.91 +273.76% +43.44% +230.31 0 Comment
JF9383 42.86 12/6/2017 Outperform 5Y $18.44 +263.02% +40.95% +222.07 0 Comment
jeepdrew222 62.03 12/12/2017 Outperform 5Y $18.61 +259.70% +38.99% +220.71 0 Comment
portefeuille 98.23 3/27/2017 Outperform 5Y $18.50 +261.84% +59.75% +202.09 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CRSP.